| Resumo: |
The leishmaniase is a serious public health problem in the world, demanding effective measures for its control and treatment. The patient's immune response in visceral leishmaniasis has a fundamental role in the prognosis of this infection inflammation, which can be fatal if untreated. So that chemotherapy can result in healing, it is important that the immune system is able and necessary stimulus to the development of appropriate cytokine profile and disease resistance to fighting agent.Thus, the purpose of this study was to evaluate the levels serum of patients on the adjuvant action of N-acetyl-L-cysteine (NAC) in the chemotherapy of human visceral leishmaniasis, made with pentavalent antimony. From an intervention study, clinical trial, blinded, randomized, 60 patients were investigated at the University Hospital with the diagnosis of visceral leishmaniasis. These patients were divided into two groups of 30: Study Group - which made use of pentavalent antimony standard dose supplemented with N-acetyl-L-cysteine (NAC) and the control group - which only used a standard dose of antimony. This study was approved by the ethics committee in search of UFS under CAAE 0151.0.107.000-07 number. The patients selected randomly and were assessed for clinical and laboratory parameters. To evaluate the rate of the patients were performed serum levels of cytokines IFN-γ, TNF-α, IL-10, IL-12p40 and of molecule sCD40L before, during and after treatment using the Luminex 100 analyzer. The results suggest that the addition of NAC to conventional therapy improves the immune response of patients, especially in lowering serum levels of IL-10, IL-12p40 and elevated sDC40L. This study showed that although both groups had healed up on the last day of treatment, the study group developed a response indicative of early healing, sugesting that the NAC has acted in a manner adjunct to pentavalent antimony, being also proposed the use of the sCD40L molecule as a prognostic marker for visceral leishmaniasis. |
|---|
